CEO Converts $10.5M in Preferred Stock to Common Shares
Summary
Sensei Biotherapeutics' CEO, Parikh Anand Kiran, converted over $10.5 million worth of Series B Preferred Stock into common shares, significantly increasing his direct common stock ownership as a result of a prior merger agreement.
Key Events
-
CEO Converts Preferred Stock
CEO Parikh Anand Kiran converted 761.428 shares of Series B Preferred Stock into 761,428 shares of common stock on June 15, 2026.
-
Significant Ownership Shift
The conversion represents a $10,545,778 transaction, significantly increasing the CEO's direct common stock holdings, representing over 56% of the company's market capitalization.
-
Post-Merger Transaction
This conversion is a mechanical step related to the February 2026 merger agreement and subsequent recapitalization, solidifying the CEO's direct common stock ownership.
Analysis
This Form 4 reports a substantial conversion of Series B Preferred Stock into common stock by CEO Parikh Anand Kiran, valued at over $10.5 million. While a conversion (Code C) is a mechanical transaction rather than a discretionary open-market purchase, it significantly increases the CEO's direct exposure to the common stock's performance. This transaction is a direct outcome of the company's recent transformative acquisition and private placement, aligning the CEO's incentives more closely with common shareholders.
At the time of this filing, SNSE was trading at $13.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.6M. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.